期刊文献+

心脑血管病诊治中血脂检验的临床运用研究 被引量:14

Brain Lipids Tested in Clinical Diagnosis and Treatment of Heart Vascular Disease
下载PDF
导出
摘要 目的探讨分析心脑血管病诊治中血脂检验的临床运用价值。方法选取我院2013年2月~2015年9月收治的90例心脑血管患者,根据病情分成甲组(n=45,心血管病患者)、乙组(n=45,脑血管病患者),择同期50例健康体检者为对照组。对3组受检者的血脂检验结果予以观察对比。结果甲组、乙组的血浆粘度、红细胞聚集指数高于对照组(P〈0.05),红细胞变形性低于对照组(P〈0.05),但甲组与乙组比较差异无统计学意义(P〉0.05);在甘油三酯、总胆固醇、低密度脂蛋白、高密度脂蛋白、载脂蛋白A-1、载脂蛋白B方面,甲组、乙组相较于对照组,差异有统计学意义(P〈0.05)。结论血脂检验在心脑血管病诊治中具有非常重要的作用,可以为临床治疗提供参考依据。 Objective To investigate the clinical application value of lipid testing in diagnosis and treatment for heart brain vascular disease. Methods From February 2013 to September 2015, 90 cases of cardiovascular patients were selected, according to the disease into Group A(n = 45, patients with cardiovascular disease), Group B(n = 45, cerebrovascular disease patient), chose the same period 50 cases of healthy control group. Test results on blood lipids in three groups of subjects were observed and compared. Results Plasma viscosity, erythrocyte aggregation index in Group A and Group B were significantly higher than control group(P〈0. 05), red blood cell deformability was significantly lower than the control group(P〈0. 05), but there was no difference between group A and group B(P〈0. 05), in triglycerides, total cholesterol, low density lipoprotein, high density lipoprotein, apolipoprotein a-1, apolipoprotein aspect B in group A, group B compared to the control group, the difference was significant(P〈0. 05). Conclusion The diagnosis and treatment of cardiovascular diseases brain lipid testing has a very important role, can provide a reference for clinical treatment.
作者 姚伟
出处 《中国继续医学教育》 2016年第3期55-56,共2页 China Continuing Medical Education
关键词 心脑血管病 诊治 血脂检验 Cardiovascular disease Treatment Lipid test
  • 相关文献

参考文献5

二级参考文献26

  • 1B. Isomaa, P. Almgren, T. Tuomi et al. Cardiovascular morbidity and mortality associated with the metabolie syndrome. Diabetes Care ,2001,24:683-689.
  • 2H. M. Lakka, D. E. Laaksonen,T. A. Lakka et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA ,2002,288:2709-2716.
  • 3P. M. Ridker,J. E. Buring,N. R. Cook and N. Rifai,C-reactive protein,the metabolic syndrome, and risk of incident cardiovascular events : an 8-year follow-up of 14 719 initially healthy American women. Circulation ,2003,107:391-397.
  • 4A. O. Rantala, H. Kauma, M. Lilja et al. Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects. J Intern Med, 1999,245 : 163-174.
  • 5Gorter PM, Olijhoek JK, Graaf Y, et al. Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease,peripheral arterial disease or abdominal aortic aneurysm. Atherosclerosis ,2004,173 : 361-367.
  • 6Yaffe K, Knanya A,Lindquist K, et al. The Metabolic Syndrome, Inflammation, and Risk of Cognitive Decline. JAMA ,2004,292:2237-2242.
  • 7de Ferranti ST, Gauvrcau K, Ludwig DS, et al. Prevalence of the Metabolic Syndrome in American Adolescents. Circulation ,2004,110:2494-2497.
  • 8Haverate F, Thompson SG, Pyke SD, et al. Production of C reaction pro-tein and risk of coronary events in stable and unstable angina: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet, 1997,349:462 -466.
  • 9Koenig W, Khuseyinova N, Lowel H, et el. Lipoprotein-assoeiated phospholipase A2 adds to risk prediction of incident coronary events by Creactive protein in apparently healthy middle-e.ged men from the general population: results from the 14-year follow-up of a large cohort fromsouthern Germany. Circulation ,2004,110 : 1903-1908.
  • 10Akbiyik F, Ray DM, Gettings KF, et al. Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes.Blood ,2004,104 : 1361-1368.

共引文献43

同被引文献65

引证文献14

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部